Anokion is a clinical-stage biotechnology company that focuses on developing innovative therapies for autoimmune diseases by promoting immune tolerance. Their proprietary platform utilizes engineered proteins, or antigens, that specifically target receptors on liver cells. This approach leverages the liver's unique immunological properties, which allow it to process both harmful and harmless antigens. By educating the immune system to recognize certain self-antigens as non-threatening, Anokion aims to modulate the harmful inflammatory responses typically seen in autoimmune conditions. This method is akin to vaccination, where the immune system learns to ignore specific self-cells rather than attacking them.

The company's lead product candidates, such as KAN-101 for celiac disease and ANK-700 for multiple sclerosis, are designed to induce immune tolerance and potentially modify the disease course. Anokion's clinical trials, including the ongoing Phase 1b/2 ACeD-it trial for KAN-101, have shown promising safety and efficacy results, indicating the potential for these therapies to provide durable treatment options for patients. By harnessing the liver's natural tolerance pathways, Anokion seeks to transform the landscape of autoimmune disease treatment, offering a targeted approach that minimizes the side effects associated with traditional immunosuppressive therapies.

United States

Anokion SA is a Swiss biotechnology company that aims to make a meaningful difference in the lives of patients suffering from autoimmune diseases by restoring normal immune tolerance. The company is focused on both prevalent and rare autoimmune diseases, including celiac disease, multiple sclerosis and type 1 diabetes. Anokion’s distinct approach leverages the company’s immune-based platform, which targets natural pathways in the liver to restore immune tolerance and address the underlying cause of autoimmune disease.

Anokion

Company Details